Nanjing Indetek Pharmaceutical Technology

Nanjing Indetek Pharmaceutical Technology, also known as Indetek Laboratory or Yuxi Pharmaceutical, is a clinical-stage biopharmaceutical company specializing in innovative dermatological treatments. Founded in 2020 and headquartered in Shanghai and Nanjing, the company utilizes its proprietary ILDS® (Innovative Liquid Delivery System) transdermal platform to develop therapies with enhanced penetration and patient compliance. Its lead product, IDT-001 (Impetine®), is a topical mupirocin gel for impetigo that reached the New Drug Application (NDA) stage in China in late 2025. The company's pipeline also includes IDT-003, a Phase 2 candidate for melasma, and various programs targeting acne and alopecia. Indetek has established strategic collaborations with Fudan University and has received backing from prominent investors including 3E Bioventures and Jiuyou Capital.